24 November, 2020

Capital Markets Day

The virtual Capital Markets Day consisted of presentations from Active Biotech executives and international experts. This was followed by a live Q&A webcast. Links to the presentations are found further down on this page.

A replay of the live webcast can be seen in the player below.


Welcome and Introduction

Presented by Helén Tuvesson

Laquinimod – Treatment of Inflammatory Eye Disorders

Presented by Helena Eriksson

Tasquinimod – Treatment of Multiple Myeloma

Presented by Helén Tuvesson

An Introduction to Multiple Myeloma

Presented by Axel Glasmacher

A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma

Presented by Dan Vogl

Naptumomab – Next generation immunotherapy capable of targeting cold tumors

Presented by Asher Nathan


Helén Tuvesson


Helén has a Ph.D in cell and molecular biology in Medical Science and more than 25 years of experience in leading drug development in senior positions.

Helena Eriksson


Helena has a Ph.D in experimental hematology in Medical Science and has more than 25 years of experience in the pharmaceutical industry.

Axel Glasmacher

Dr. med.

Adjunct professor of medicine at the University of Bonn, Germany.

Previous Head of Global Clinical R&D and Senior Vice President for Celgene.

Member of the Board at Active Biotech

Dan Vogl


Director, Abramson Cancer Center Clinical Research Unit and Associate Professor of Medicine at the University of Pennsylvania, US.

Principal Investigator Phase 1b/2a clinical study with Tasquinimod.

Asher Nathan


Asher is the CEO of Neotx Therapeutics, a clinical stage immunotherapy company. Since 2016, Active Biotech has a license agreement with NeoTX for the global development and commercialization of naptumomab for cancer treatment.